Satraplatin and Vinorelbine in Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
Vinorelbine (NVB) and platinum compounds are anticancer agents with broad spectrum of
efficacy, clinically and preclinically proven synergism and only partially overlapping
toxicities. Combinations with vinorelbine and platinum compounds with limited neurotoxicity
are among the most used palliative regimens in a variety of solid tumors, including NSCLC,
breast and cervical cancer. The oral platinum analogue satraplatin (SATRA) has been brought
into clinical development because of the antitumor activity and toxicity comparable to those
of carboplatin, together with a good acceptability of the oral administration.The recent
availability of oral formulation of anticancer agents of proven efficacy in some indications
is likely to become a valid option which could affect clinical daily management. The oral
administration of vinorelbine and satraplatin might represent a reasonable option of
palliative treatment in patients with advanced breast cancer, NSCL, GU or GY tumors for which
a curative treatment can not be provided.